Mammalian target of rapamycin signaling is involved in the vasculogenic mimicry of glioma via hypoxia-inducible factor-1α

Oncology Reports

Volumn 32, Issue 5, 2014, Pages 1973-1980

  Huang, Min ^a   Ke, Yiquan ^a   Sun, Xinlin ^a   Yu, Li ^a   Yang, Zhilin ^a   Zhang, Yonghong ^a   Du, Mouxuan ^a   Wang, Jihui ^a   Liu, Xiao ^a   Huang, Shuyun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Hypoxia inducible factor 1 ; Mammalian target of rapamycin; Vascular targeted therapy; Vasculogenic mimicry

Indexed keywords

GELATINASE A; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE 14; HIF1A PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ARTICLE; CANCER GRADING; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR MIMICRY; PROTEIN ANALYSIS; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULOGENIC MIMICRY; AGED; CELL HYPOXIA; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IN VITRO TECHNIQUES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84907292811     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3454     Document Type: Article

References (44)

1. Ahmadloo N, Kani AA, Mohammadianpanah M, et al: Treatment outcome and prognostic factors of adult glioblastoma multiforme. J Egypt Natl Canc Inst 25: 21-30, 2013.
2. Reardon DA, Herndon JE II, Peters K, et al: Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 107: 213-221, 2012.
3. Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu GL: Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res 31: 16, 2012.
4. Maniotis AJ, Folberg R, Hess A, et al: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155: 739-752, 1999.
5. Wang SY, Ke YQ, Lu GH, et al: Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma. J Neurooncol 112: 339-345, 2013.
6. Wang SY, Yu L, Ling GQ, et al: Vasculogenic mimicry and its clinical significance in medulloblastoma. Cancer Biol Ther 13: 341-348, 2012.
7. Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4: 51, 2011.
8. Land SC and Tee AR: Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 282: 20534-20543, 2007.
9. Su M, Feng YJ, Yao LQ, et al: Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer 18: 476-486, 2008.
10. Paulis YW, Soetekouw PM, Verheul HM, Tjan-Heijnen VC and Griffioen AW: Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 1806: 18-28, 2010.
11. Zhu P, Ning Y, Yao L, Chen M and Xu C: The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J Exp Clin Cancer Res 29: 124, 2010.
12. Snijder B, Sacher R, Ramo P, et al: Single-cell analysis of population context advances RNAi screening at multiple levels. Mol Syst Biol 8: 579, 2012.
13. Liu R, Yang K, Meng C, Zhang Z and Xu Y: Vasculogenic mimicry is a marker of poor prognosis in prostate cancer. Cancer Biol Ther 13: 527-533, 2012.
14. Sun W, Shen ZY, Zhang H, et al: Overexpression of HIF-1α in primary gallbladder carcinoma and its relation to vasculogenic mimicry and unfavourable prognosis. Oncol Rep 27: 1990-2002, 2012.
15. Comito G, Calvani M, Giannoni E, et al: HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51: 893-904, 2011.
16. Abraham RT: mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279: 299-319, 2004.
17. Wang L, Zhang ZG, Zhang RL, et al: Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-Activated endothelial cells promote neural progenitor cell migration. J Neurosci 26: 5996-6003, 2006.
18. Ahmadi SA, Moinfar M, Gohari Moghaddam K and Bahadori M: Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma. Arch Iran Med 13: 498-503, 2010.
19. Sharma N, Seftor RE, Seftor EA, et al: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50: 189-201, 2002.
20. van der Schaft DW, Hillen F, Pauwels P, et al: Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res 65: 11520-11528, 2005.
21. Liu WB, Xu GL, Jia WD, et al: Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma. Med Oncol 28: S228-S238, 2011.
22. Sun T, Sun BC, Zhao XL, et al: Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coactivation by Bcl-2 and Twist1: a study of hepatocellular carcinoma. Hepatology 54: 1690-1706, 2011.
23. Baeten CI, Hillen F, Pauwels P, de Bruine AP and Baeten CG: Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52: 2028-2035, 2009.
24. Yue WY and Chen ZP: Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53: 997-1002, 2005.
25. Sun B, Zhang D, Zhang S, Zhang W, Guo H and Zhao X: Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249: 188-197, 2007.
26. Zhao N, Sun BC, Sun T, et al: Hypoxia-induced vasculogenic mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol 29: 3599-3607, 2012.
27. Gomez-Pinillos A and Ferrari AC: mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am 26: 483-505, 2012.
28. Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell 12: 9-22, 2007.
29. Li XY, Zhang LQ, Zhang XG, et al: Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas. J Neurooncol 103: 453-458, 2011.
30. Itzhaki O, Greenberg E, Shalmon B, et al: Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One 8: e57160, 2013.
31. Serwe A, Rudolph K, Anke T and Erkel G: Inhibition of TGF-β signaling, vasculogenic mimicry and proinflammatory gene expression by isoxanthohumol. Invest New Drugs 30: 898-915, 2012.
32. Iwamaru A, Kondo Y, Iwado E, et al: Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26: 1840-1851, 2007.
33. Li C, Liu Y, Liu J, et al: Rapamycin inhibits human glioma cell proliferation through down-regulating mammalian target of rapamycin pathway and up-regulating microRNA-143. Head Neck Oncol 4: 66, 2012.
34. Heimberger AB, Wang E, McGary EC, et al: Mechanisms of action of rapamycin in gliomas. Neuro Oncol 7: 1-11, 2005.
35. Misra RM, Bajaj MS and Kale VP: Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1α-neuropilin-1 axis. PLoS One 7: e50153, 2012.
36. Hendrix MJ, Seftor EA, Meltzer PS, et al: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 98: 8018-8023, 2001.
37. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE and Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 5: 228-233, 2006.
38. Chen LX, He YJ, Zhao SZ, et al: Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 11: 229-235, 2011.
39. Hess AR, Seftor EA, Seftor RE and Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 63: 4757-4762, 2003.
40. Seftor RE, Seftor EA, Kirschmann DA and Hendrix MJ: Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther 1: 1173-1179, 2002.
41. Kirschmann DA, Seftor EA, Hardy KM, Seftor RE and Hendrix MJ: Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 18: 2726-2732, 2012.
42. Cao Z, Bao M, Miele L, Sarkar FH, Wang Z and Zhou Q: Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: a systemic review and meta-Analysis. Eur J Cancer 49: 3914-3923, 2013.
43. Ballou LM and Lin RZ: Rapamycin and mTOR kinase inhibitors. J Chem Biol 1: 27-36, 2008.
44. Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell 149: 274-293, 2012.